Peter C Ulrich, 742612 N Paulina St, Chicago, IL 60614

6420188, Jul 16, 2002

Feb 16, 1996

08/602929

Richard Bucala - New York NY
Peter C. Ulrich - Old Tappan NJ
Xini Xhang - Jericho NY
Anthony Cerami - Shelter Island NY

The Picower Institute for Medical Research - Manhasset NY

G01N 3353

436500, 435 71, 549490, 549491

The present invention encompasses assays to identify compounds that inhibit the enzymatic activity of MIF which catalyzes the tautomerization of MIF-substrates, such as D-dopachrome to DHICA. In general, the assay is conducted in vitro by adding, mixing or combining MIF and a suitable substrate in the presence or absence of a test compound, and measuring the tautomerization of the substrate. The test compounds that inhibit tautomerization in the assay are identified as MIF inhibitors.

6615842, Sep 9, 2003

Jun 26, 2000

09/603633

Anthony Cerami - Sleepy Hollow NY
Carla Cerami - Sleepy Hollow NY
Peter Ulrich - Portland OR

Cerami Consulting Corp. - Tarrytown NY

A24D 306

131331, 131332

This invention provides methods, devices and agents for the removal of nucleophilic toxins present in tobacco and tobacco smoke. The filter element of a tobacco smoking device or an air filtration device used in conjunction with a tobacco smoking device may comprise chemical moieties reactive with nucleophilic compounds, or agents that trap nucleophilic compounds may be incorporated into the filter element of tobacco smoking device such as a cigarette, cigar, pipe, or in a separate filter through which tobacco smoke passes before entering the mouth. The agents may also be incorporated into air filters for removing tobacco combustion product toxins from room air. The agents may also be incorporated into smoking or smokeless tobacco to remove toxins.

6649797, Nov 18, 2003

Jun 25, 2001

09/887020

Michael I. Bukrinsky - Potomac MD
Anthony Cerami - Sleepy Hollow NY
Peter Ulrich - Portland OR
Bradley Berger - Medicine Hat, CA

The Picower Institute for Medical Research - Manhasset NY

C07C21100

564305, 514197, 514319, 514211, 514264, 514323, 568335, 436 86, 436111, 436128

The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught.

6689777, Feb 10, 2004

Oct 23, 2002

10/278729

Peter C. Ulrich - Portland OR
Anthony Cerami - Croton-on-Hudson NY

Kenneth S. Warren Institute - Ossining NY

C07D27760

5142328, 51425213, 514366, 544133, 544368, 548150

The present invention is directed to substituted naphthothiazolium, aromatic guanylhydrazones, and other compounds and compositions with anti-malarial activity useful for the treatment and prophylaxis of malaria. The compounds are provided for the treatment of malaria or the sequelae of malarial infection, for depolymerizing malaria pigment (hemozoin), and for ameliorating the adverse effects of hemozoin on host cells.

6777557, Aug 17, 2004

Feb 7, 2002

10/072712

Peter C Ulrich - Portland OR, 97229
Sheng Ding Fang - Mount Kisco NY, 10549
Michael L Brines - Woodbridge CT, 06525
Qiao-Wen Xie - Yonkers NY, 10710
Anthony Cerami - Sleepy Hollow NY, 10591

C07D27784

548366, 548150

In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

6790859, Sep 14, 2004

Jan 21, 2003

10/348378

Dilip R. Wagle - Nanuet NY
Taikyun Rho - Saddle Brook NJ
John J. Egan - NY NY
Sara Vasan - Yonkers NY
Peter Ulrich - Old Tappan NJ
Anthony Cerami - New York NY

Alteon Incorporated - Parsippany NJ

A61K 31425

514365

The present invention relates to compositions and methods for reversing advanced glycosylation end product-mediated cross-linking and protein aging. Accordingly, compositions are described which comprise thiazolium compounds substituted with heterocyclic groups which are capable of reversing the formation of advanced glycosylation end product cross-links. Both industrial and therapeutic applications for the invention are disclosed, as food spoilage and animal protein aging can be treated. Such compounds have particular application in the treatment of protein aging such as is responsible for the complications of aging and diabetes.

6906076, Jun 14, 2005

Sep 12, 2003

10/660748

Michael I. Bukrinsky - Potomac MD, US
Anthony Cerami - Sleepy Hollow NY, US
Peter Ulrich - Portland OR, US
Bradley Berger - Medicine Hat, CA

Cytokine Pharmasciences, Inc. - King of Prussia PA

A61K031/505
C07D239/28

514256, 514269, 514634, 514637, 514689, 436 86, 436111, 436128, 544264, 544276, 544277, 544319, 544321, 544323, 544326, 544332, 544335, 564237, 564244, 564305, 568 42, 568 43, 568308, 568329, 568331, 568335, 568337

The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught.

7022721, Apr 4, 2006

Mar 8, 2004

10/794024

Peter C Ulrich - Portland OR, US
Sheng Ding Fang - Mount Kisco NY, US
Michael L Brines - Woodbridge CT, US
Qiao-Wen Xie - Yonkers NY, US
Anthony Cerami - Sleepy Hollow NY, US

A61K 31/428
C07D 277/84

514366, 548366, 548150

In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.